Categories: News

Avantor® to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

RADNOR, Pa., June 1, 2022 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verde, Calif. on Tuesday, June 14, at approximately 11:00 a.m. Eastern Daylight Time

A live webcast can be accessed on the investors section of our website and a replay will be available for approximately 90 days.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

Media Contact
Petro Kacur
Director, PR & External Communications
Avantor
404-408-0663
Petro.Kacur@avantorsciences.com

View original content:https://www.prnewswire.com/news-releases/avantor-to-participate-in-the-43rd-annual-goldman-sachs-global-healthcare-conference-301558315.html

SOURCE Avantor and Financial News

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

2 hours ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

2 hours ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

5 hours ago